^
    22h
    Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study (clinicaltrials.gov)
    P2, N=37, Recruiting, Ningbo Medical Center Lihuili Hospital
    New P2 trial • IO biomarker
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab)
    1d
    NeoART: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Suspended --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • oxaliplatin
    1d
    NIVO402025: Phase II Open-lable Single-center Clinical Study of the Efficacy and Safety of Low-dose Immunotherapy in the Treatment of Patients With Metastatic and Locally Advanced Colorectal and Gastric Cancers With Microsatellite Unstable Phenotype (MSI)/Deficiency of Mismatch Repair System (dMMR) (clinicaltrials.gov)
    P2, N=128, Enrolling by invitation, Blokhin's Russian Cancer Research Center
    New P2 trial • Mismatch repair • dMMR
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • 5-fluorouracil
    1d
    A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=190, Recruiting, Taizhou Hanzhong biomedical co. LTD | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment open • Trial primary completion date • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • Puyouheng (pucotenlimab)
    1d
    PK equivalence: A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=387, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    HCC-SIGHT: A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=350, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Stivarga (regorafenib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    2d
    Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients (clinicaltrials.gov)
    P2/3, N=156, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2028 --> Dec 2029
    Trial completion date • pMMR
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)
    2d
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov)
    P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab)
    3d
    ECLYPse: Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium
    5d
    Case Report: Prostate adenocarcinoma with peritoneal carcinomatosis and elevated CEA mimicking colorectal cancer: a diagnostic dilemma. (PubMed, Front Oncol)
    He achieved an excellent response to androgen deprivation therapy (ADT) combined with abiraterone and prednisone, maintaining an undetectable prostate-specific antigen (PSA) level for over 2 years...The patient transitioned to docetaxel plus ADT, resulting in symptomatic improvement and partial radiologic response...Second, standard markers such as PSA and immunohistochemistry may be misleading in atypical presentations. Finally, the case highlights the decisive role of molecular diagnostics, specifically NGS, in identifying tumor origin and preventing misdiagnosis.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2)
    |
    docetaxel • 5-fluorouracil • abiraterone acetate • prednisone • leucovorin calcium
    5d
    HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study. (PubMed, ESMO Gastrointest Oncol)
    Of note, 6/7 cases with HER-2 mutations exhibited limited benefit from treatment with FOLFIRI plus cetuximab with PFS inferior to 8 months. Taken together, these results highlight the need to test HER-2 gene alterations for patients with RAS/BRAF V600 WT, MSS mCRC, who are candidates for anti-epidermal growth factor receptor therapies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    HER-2 positive • HER-2 overexpression • BRAF mutation • HER-2 amplification • HER-2 negative • BRAF V600 • HER-2 mutation • BRAF wild-type • HER-2 positive + HER-2 overexpression
    |
    FoundationOne® CDx
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium
    5d
    DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer. (PubMed, ESMO Gastrointest Oncol)
    Gastric or gastroesophageal junction (GEJ) cancers are usually diagnosed at advanced stages with poor prognoses and 5-year survival rates. DESTINY-Gastric05 (NCT06731478) is a global, multicenter, open-label, randomized, phase III trial to evaluate the efficacy and safety of first-line T-DXd 5.4 mg/kg plus 5-fluorouracil or capecitabine and pembrolizumab versus platinum-based chemotherapy with trastuzumab and pembrolizumab in patients with unresectable, locally advanced or metastatic, centrally confirmed HER2-positive (immunohistochemistry 3+ or immunohistochemistry 2+/in situ hybridization positive) gastric or GEJ cancer with a PD-L1 CPS ≥1. An exploratory cohort is to evaluate T-DXd plus 5-fluorouracil or capecitabine in patients with PD-L1 CPS <1.
    P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • EGFR positive
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine